Adicet Bio, Inc. (ACET)
NASDAQ: ACET · Real-Time Price · USD
0.5905
+0.0130 (2.25%)
Nov 21, 2025, 11:37 AM EST - Market open
Adicet Bio Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
152
Market Cap
95.48M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 24.99M | 15.26M | 156.83% |
| Dec 31, 2021 | 9.73M | -8.17M | -45.65% |
| Dec 31, 2020 | 17.90M | 16.91M | 1,699.30% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ACET News
- 15 days ago - Adicet Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates - Business Wire
- 20 days ago - Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 24 days ago - Adicet Bio to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference - Business Wire
- 5 weeks ago - Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment-Refractory Rheumatoid Arthritis (RA) - Business Wire
- 6 weeks ago - Adicet Bio, Inc. - Special Call - Seeking Alpha
- 6 weeks ago - Adicet Bio's Lupus Trial Delivers 100% Response, Setting Stage For Phase 2 - Benzinga
- 6 weeks ago - Adicet Bio, Inc. Announces $80 Million Registered Direct Offering - Business Wire
- 6 weeks ago - Adicet Bio Announces Positive Preliminary Data from ADI-001 Phase 1 Study in Patients with Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE) - Business Wire